Format

Send to

Choose Destination
Drug Discov Today. 2011 Oct;16(19-20):891-7. doi: 10.1016/j.drudis.2011.09.010. Epub 2011 Sep 18.

A challenging drug development process in the era of personalized medicine.

Author information

1
Dx-Rx Institute, Baunevaenget 76, DK-3480 Fredensborg, Denmark. jan.trost@dx-rx.dk

Abstract

After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.

PMID:
21945860
DOI:
10.1016/j.drudis.2011.09.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center